TROP2在卵巢浆液性囊腺癌中的表达及其与预后的关系

Overexpression of TROP2 is Associated with Prognosis in Ovarian Serous Cystadenocarcinoma

目的:探讨TROP2在不同卵巢组织中的表达及其与卵巢浆液性囊腺癌患者临床病理因素之间的关系,明确TROP2表达是否与卵巢浆液性囊腺癌患者预后有关。方法:应用免疫组化法检测TROP2在98例卵巢浆液性囊腺癌组织及50例正常卵巢组织中的表达情况,分析TROP2表达与卵巢浆液性囊腺癌患者临床病理特征的关系,采用COX比例风险回归模型分析影响卵巢浆液性囊腺癌患者预后的因素。结果:TROP2在卵巢浆液性囊腺癌、正常卵巢组织中的表达阳性率分别为55.1%及24.0%,差异有统计学意义(P<0.05)。TROP2表达与卵巢浆液性囊腺癌患者年龄无显著相关(P>0.05),而与患者有无淋巴结转移,组织学分级和临床分期有显著相关(P<0.05);临床分期、病理组织学分级、术后残余灶大小、TROP2基因表达均为影响卵巢浆液性囊腺癌患者预后的危险因素(P<0.05)。结论:TROP2可能成为卵巢浆液性囊腺癌患者治疗的新靶点。

Objective： To study the expression of TROP2 in different ovarian tissues and the relationship between TROP2 expression and clinicopathologic factors of ovarian serous cystadenocarcinoma and prognosis of patients. Methods： The TROP2 expression was assessed by immunohistochemistry in 98 specimens of ovarian serous cystadenocarcinoma and 50 specimens of normal ovarian tissues. A correlation was analyzed between TROP2 expression and clinical pathological features of ovarian serous cystadenocarcinoma. The COX proportional hazard regression model was used to analyze the factors affecting the prognosis of ovarian serous cystadenocarcinoma patients. Results： The TROP2 positive expression rates in the ovarian serous cystadenocarcinoma and control groups were 55.1 % and 24.0 %, respectively（P〈0.05）. TROP2 protein expression was not related to age of the patients with ovarian serous cystadenocarcinoma（P〉0.05）, but associated with lymph nodes metastasis, histological grade and clinical stage（P〈0.05）.Histological grade, clinical stage, residual tumor size and TROP2 expression were prognostic factors of ovarian serous cystadenocarcinoma. Conclusions： TROP2 may be a promising therapy target for ovarian serous cystadenocarcinoma.